The Latest Breaking News from Eli Lilly

As the earnings season nears its close, here are five ‘Strong Buy’-rated stocks that delivered exceptional earnings results.

Eli Lilly has significantly outperformed the broader market over the past year, and Wall Street analysts are bullish about the stock’s prospects.

The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +2.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.76%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +3.06%. US stocks on Thursday settled sharply higher. Stocks rallied Thursday after US weekly initial...

Initial jobless claims fell more than expected last week, which helped calm fears of a slowing labor market.

The S&P 500 Index ($SPX ) (SPY ) today is up +1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.24%. US stocks are trading higher today after US weekly initial unemployment claims fell more...

Eli Lilly stock is surging after the pharma giant beat Q2 estimates and lifted its full-year outlook. Here's what you need to know.

The S&P 500 Index ($SPX ) (SPY ) today is up +0.99%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.81%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.10%. US stocks are trading higher today after US weekly initial unemployment claims fell more...

Danish company, which also makes Ozempic, faces increasing competition from US rival Eli Lilly

Down 96% from all-time highs, AbCellera Biologics is a biotech stock with massive upside potential, given consensus price target estimates.

Tirzepatide, a drug for diabetes and obesity, has sent the 148-year-old pharma giant on a wild ride. It’s now the ninth most valuable company in the world.

Their strong fundamentals, brand strength, and drive to succeed could propel their stock higher.